Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
Synthetic Biologics, Inc. (NYSE American: SYN) will release its operational highlights and financial results for the quarter ended June 30, 2021, on August 5, 2021. The company is focused on developing microbiome therapeutics for gastrointestinal diseases with high unmet needs. Key candidates include SYN-004, aimed at preventing microbiome damage and infections, and SYN-020, targeting local and systemic GI diseases. A conference call is scheduled for the same day at 4:30 p.m. ET, with dial-in details included.
- Focus on developing therapeutics for high unmet needs in gastrointestinal diseases.
- Scheduled release of operational highlights and financial results indicates potential transparency.
- None.
ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1-412-902-4280
Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/41790. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/41790 beginning approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2021-second-quarter-operational-highlights-and-financial-results-on-august-5-2021-301342530.html
SOURCE Synthetic Biologics, Inc.
FAQ
When will Synthetic Biologics report its financial results?
What is the ticker symbol for Synthetic Biologics?
What is SYN-004 and what does it aim to prevent?
When is the conference call scheduled for Synthetic Biologics?
What are the lead candidates developed by Synthetic Biologics?
